T2EVOLVE

Accelerating the Development and Improving Access to CAR and TCR engineered T cell therapy

This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 875171.

192,000

5 years

UNIVERSITAETSKLINIKUM WUERZBURG - KLINIKUM DER BAYERISCHEN JULIUSMAXIMILIANS- UNIVERSITAT (UKW), GERMANY

VIEW PARTNERS >

2.UNIVERSITA VITA-SALUTE SAN RAFFAELE (USR), ITALY
3. UNIVERSITY COLLEGE LONDON (UCL), UK
4. ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
(AMC), NETHERLANDS
5. INSTITUT NATIONAL DU CANCER GIP, FRANCE
6. INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), FRANCE
7. BUNDESINSTITUT FUR IMPFSTOFFE UND BIOMEDIZINISCHE ARZNEIMITTEL
(PEI), GERMANY
8. OSPEDALE PEDIATRICO BAMBINO GESU (OPBG), ITALY
9. MEDIZINISCHE UNIVERSITAET WIEN (MUW), AUSTRIA
10. CONSORCI INSTITUT D’INVESTIGACIONS BIOMEDIQUES AUGUST PI I SUNYER
(IDIBAPS) SPAIN
11. FRAUNHOFER GESELLSCHAFT ZUR FOERDERUNG DER ANGEWANDTEN
FORSCHUNG E.V. (Fraunhofer), GERMANY
12. TECHNISCHE UNIVERSITAET MUENCHEN (TUM), GERMANY
13. T-CURX GMBH (T-CURX) GERMANY
14. EUROPEAN CANCER PATIENT COALITION (ECPC), BELGIUM
15. BIOSCI CONSULTING BVBA (BIOSCI), BELGIUM
16. UNIVERSIDAD DE NAVARRA (UNAV), SPAIN
17. ERASMUS UNIVERSITEIT ROTTERDAM (ESHPM), NETHERLANDS
18. MILTENYI BIOTEC BV & CO KG (MB), GERMANY
19. FUNDACIO PRIVADA INSTITUT DE RECERCA DE L’HOSPITAL DE LA SANTA
CREU I SANT PAU (IR-HSCSP), SPAIN
20. INFORMATION TECHNOLOGY FOR TRANSLATIONAL MEDICINE (ITTM)
SA (ITTM), LUXEMBOURG
21. BAYER AKTIENGESELLSCHAFT (BAYER), GERMANY
22. JANSSEN PHARMACEUTICA NV (JANSSEN), BELGIUM

This project is funded by the European Union

Why it matters

The aim of the project T2EVOLVE is to build a sustainable innovation ecosystem that will support the development of advance engineered T cell therapy to a level where every European cancer patient in need has access to safe and effective T cell products. How? The optimization of preclinical models, analytical monitoring, lymphodepletion regimens will enhance the development of safer and more effective engineered T cell therapies by reducing the toxicity observed in clinical trials and improve the success rate of clinical trials. A strategic aim of the project is to take an advantage on the tremendous potential that exists in Europe and close the gap in clinical and commercial translation in order to bring the EU back to the forefront of this global movement.

What ECPC does

ECPC will assist the T2EVOLVE project by engaging in patient involvement in the R&D process, co-development of patient friendly communication tools to improve the patient journey (M4-60)
co-development of tools and materials to help HCPs better respond to patient needs, patient-centered Health Technology Assessment of engineered T cell therapy and the creation of a roadmap for engineered T-cell therapy (online white paper).